Physician profile
Nicole M Devoe
NPI 1023489382
$3,498.07
in general payments reported to CMS, 2019-2025
31 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.14 · 2022: $450 · 2023: $586 · 2024: $1,117 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.44 |
| Education | $353.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.42 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $396.25 | 2024-2025 | |
| Janssen Biotech, INC. | $329.49 | 2024-2025 | Tremfya |
| Amgen INC. | $271.09 | 2021-2025 | Otezla, Otezla, Evenity |
| Pfizer INC. | $259.93 | 2022-2025 | |
| Lilly USA, LLC | $220.82 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $215.05 | 2022-2025 | Sotyktu, Eliquis |
| Genzyme Corporation | $137.34 | 2024-2025 | |
| Novo Nordisk INC | $131.06 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $78.09 | 2022-2023 | Prolastin-C Liquid |
| Leo Pharma INC. | $55.56 | 2025 | Adbry, Anzupgo |
| Incyte Corporation | $54.85 | 2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $53.68 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $48.72 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $41.33 | 2022-2023 | Gardasil 9, Vaxneuvance, Proquad |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.31 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $39.97 | 2022 | |
| Medtronic, INC. | $30.97 | 2022 | |
| Organon LLC | $26.97 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $24.25 | 2022 | |
| Ethicon US, LLC | $22.79 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.76 | 2024 | Libtayo |
| Ultragenyx Pharmaceutical INC. | $16.42 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $16.30 | 2023 | Prehevbrio |
| Galderma Laboratories, L.P. | $16.02 | 2025 | Nemluvio |
| Biogen, INC. | $15.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2022 | |
| Seqirus USA INC | $15.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.81 | 2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $12.33 | 2022 | |
| Currax Pharmaceuticals LLC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Devoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.